Skip to main content

Table 3 List of potential compounds for repurposing with anti-Zika activity, extracted from [19, 83]

From: Zika vaccines and therapeutics: landscape analysis and challenges ahead

Drug group Drug name Description
Nucleoside analogs Sofosbuvir, MK-608 • Inhibit Zika virus (ZIKV) replication in cellular assays
• Efficacious in animal models
2CMC, Ribavirin, Favipiravir, T1105 • Showed antiviral activity in cell culture
BCX4430, GS5734 • Reduced mortality in ZIKV-infected mice
• Currently in phase I and II clinical trials
Peptidomimetic agents CN-716 • Inhibit ZIKV protease in vitro, but only weakly inhibit viral replication
• Due to safety reasons, may not translate as therapeutic option for pregnant women, but could be applied to other infected individuals
Adenosine analog NITD008 • Showed potent anti-ZIKV activity
• Could serve as a reference inhibitor for future drug screen and discovery
Cyclin-dependent kinase inhibitor PHA-690509 • Showed inhibition of ZIKV replication of all three strains
Antimalaria Chloroquine • Reduces virus production, the number of infected cells, and cell death promoted by ZIKV infection without any cytotoxic effect
• Promising candidate for ZIKV clinical trials
• Can be safely administered to pregnant women since it is clinically approved
Anthelmintic Bithionol • Propagate by activating host caspases and inducing programmed cell death
Epigallocatechin gallate   • Natural compound found in food items, particularly green tea
• It inhibits ZIKV entry into host cell
Interferon-inducible transmembrane proteins   • Inhibit the replication of a number of pathogenic viruses